{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T11:06:13Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 23.0, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0954a-aa59-7253-a068-52e14377ac12\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: macitentan\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 044: 1001 regi", "usd": 0.0, "recall": true }, "codex": { "seconds": 79.9, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a0954a-aa63-76f1-a4a7-87ad70e8707b\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: macitentan\nRegistry id: vr.tr.macitentan\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\nCo" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:50:27+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "standards_and_regulation", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:32+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q6724151", "registryId": "vr.tr.macitentan", "name": "macitentan", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q6724151/", "model": { "registry_id": "vr.tr.macitentan", "name": "macitentan", "purpose": "Enable an agent to identify macitentan, assess the suitability of a particular material lot, and recognize the evidence and constraints governing its handling and pharmaceutical use.", "definition": "Macitentan is a synthetic small-molecule drug substance that antagonizes endothelin ETA and ETB receptors and is used to treat pulmonary arterial hypertension.", "scope_statement": "This model owns macitentan as the chemical substance registered as vr.tr.macitentan in PHY / PHY.MAT, including molecular identity, material state, quality, pharmacological relationships and substance-specific constraints.", "in_scope": [ "Molecular identity and identifiers distinguishing macitentan from related endothelin receptor antagonists", "Solid form, particle properties, solubility and condition-dependent stability", "Lot identity, assay, impurities and fitness for an explicitly stated use", "Endothelin receptor activity and relationships to active metabolites", "Substance hazards and links to dated, jurisdiction-specific pharmaceutical requirements" ], "out_of_scope": [ "Finished tablets, packaging, excipients and brand-specific product specifications", "Macitentan-tadalafil combination products as complete medicinal products", "Aprocitentan and other metabolites as independently modeled substances", "Manufacturing routes, equipment and process operation", "Individual prescribing decisions, patient records and pulmonary arterial hypertension care pathways" ], "distinguishing_features": [ "Match a structure-resolved identity to CAS 441798-33-0 and PubChem CID 16004692; a similar name or therapeutic class is insufficient. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Macitentan)", "Check for molecular formula C19H20Br2N6O4S and the brominated pyrimidine, ether and N-propylsulfamide connectivity; molecular mass alone cannot establish identity. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Macitentan)", "Distinguish macitentan from its related active metabolite ACT-132577 through explicit molecular structure and analytical separation. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Macitentan)", "Classify Opsumit tablets and macitentan-containing combinations through a contains-macitentan relationship, rather than treating their brand names as equivalent material identities. [PubChem](https://pubchem.ncbi.nlm.nih.gov/compound/Macitentan)" ], "characteristics": [ { "name": "Chemical identity", "kind": "category", "unit_or_values": "Structure identifier, CAS number, PubChem CID and verified synonym", "why_it_matters": "Prevents confusion between macitentan, its metabolites and finished medicines." }, { "name": "Assay and reporting basis", "kind": "measurement", "unit_or_values": "% mass fraction; as-is, dried or solvent-free basis; method and uncertainty", "why_it_matters": "A chromatographic area percentage alone does not establish the mass of macitentan available." }, { "name": "Related substances", "kind": "measurement", "unit_or_values": "% or mg/kg for each identified or unidentified impurity, with detection and quantification limits", "why_it_matters": "Controls whether related compounds or degradation products compromise the intended use." }, { "name": "Solid-state identity", "kind": "state", "unit_or_values": "Observed crystalline or amorphous state; characterized form; hydrate or solvate status; unknown", "why_it_matters": "Connects a sample's physical behavior to measured material form without assuming all lots are equivalent." }, { "name": "Solubility profile", "kind": "measurement", "unit_or_values": "mg/mL or mol/L, with solvent, pH, temperature, solid form and equilibration method", "why_it_matters": "Supports preparation of valid analytical and pharmacological solutions." }, { "name": "Thermal behavior", "kind": "measurement", "unit_or_values": "°C with method, heating rate and identification of melting, transition or decomposition", "why_it_matters": "Avoids assigning an unsupported melting or boiling point to a thermal event." }, { "name": "Particle-size distribution", "kind": "measurement", "unit_or_values": "µm; D10, D50 and D90 with dispersion and measurement method", "why_it_matters": "Helps explain differences in dissolution, sampling and powder handling." }, { "name": "Endothelin receptor activity", "kind": "measurement", "unit_or_values": "ETA and ETB assay endpoints in nM, with assay system, endpoint and exposure duration", "why_it_matters": "Separates receptor-specific experimental potency from clinical effectiveness." }, { "name": "Parent-metabolite relationship", "kind": "relation", "unit_or_values": "Macitentan to identified metabolite, with transformation and evidence", "why_it_matters": "Prevents parent concentrations and metabolite activity from being merged." }, { "name": "Material disposition", "kind": "state", "unit_or_values": "Quarantined, released for a stated use, rejected, expired or awaiting retest", "why_it_matters": "Makes permitted actions depend on lot evidence and authorization." }, { "name": "Applicable hazard and regulatory evidence", "kind": "relation", "unit_or_values": "Dated SDS, classification authority, jurisdiction, medicinal-product label and approval record", "why_it_matters": "Separates bulk-material handling requirements from medicinal-product use conditions." } ], "affordances": [ "Reconcile a supplier sample or registry record against macitentan's verified molecular identity.", "Select identity, assay and impurity measurements appropriate to the material and intended use.", "Assess whether a lot can be released, requires retesting or should remain quarantined.", "Determine evidence-supported conditions for analytical dissolution, storage and powder handling.", "Link receptor and exposure evidence to the correct parent substance or metabolite.", "Flag applicable hazard and labeling constraints for review by the responsible laboratory or clinical professional." ], "agent_conduct": { "may": [ "Identify macitentan by name, identifiers and documented properties, citing sources.", "Report approved uses and warnings, including those on pregnancy, from official product information.", "Check a material lot's certificate of analysis against its specification." ], "must_not": [ "Recommend it or a dose for a particular patient.", "Downplay or omit its pregnancy warnings when describing it.", "Supply it outside lawful pharmaceutical channels and its risk programmes.", "Present it as a cure for pulmonary arterial hypertension." ], "requires_human": [ "Any decision to start, stop or change a patient's treatment.", "Releasing or destroying a material lot." ] }, "ethics": { "considerations": [ "Harm to an unborn child is a central risk, so information on contraception and testing must be honest.", "Specialist drugs are expensive; access is a question of fairness." ], "affected_parties": [ "Patients with pulmonary hypertension", "Women who may become pregnant", "Prescribers and pharmacists" ] }, "owners": { "steward": "The marketing authorization holder for each medicine; the national medicines regulator oversees it.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identity rests on the label, batch record and certificate of analysis, not appearance.", "Packs carry pregnancy warnings required by the regulator." ], "failure_modes_and_hazards": [ "Harm to an unborn child if taken during pregnancy.", "Liver effects and falling blood counts need monitoring.", "Exposure of pregnant staff during manufacture or handling." ], "standards_and_regulation": [ "ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, International Council for Harmonisation." ], "what_it_is_for": [ "Macitentan is encountered as a pharmaceutical substance in medicine manufacture, analytical testing and research on endothelin receptors.", "Its therapeutic use concerns pulmonary arterial hypertension, while material assessment requires evidence of chemical identity, purity and formulation." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q6724151: macitentan", "url": "https://www.wikidata.org/wiki/Q6724151", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Macitentan", "url": "https://en.wikipedia.org/wiki/Macitentan", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "macitentan-identity", "name": "Macitentan identity", "description": "Establish what counts as macitentan and distinguish substance identity from associated medicines.", "rationale": "Related compounds and product names can otherwise be incorrectly merged into this registry entry.", "layers": [ { "id": "molecular-recognition", "name": "Molecular recognition", "description": "Connect structure and identifiers to evidence from the actual material.", "findings": [ { "id": "structure-confirmed-parent", "name": "Structure-confirmed parent", "description": "Require a structure match supported by appropriate analytical evidence, not merely a supplier name or nominal mass.", "questions": [ { "text": "Which authoritative structure and identifiers define macitentan for this record?", "kind": "definition", "id": "structure-confirmed-parent-q01" }, { "text": "Which reference-standard comparison and orthogonal measurements confirm the sample as macitentan?", "kind": "measurement", "id": "structure-confirmed-parent-q02" } ] } ] }, { "id": "related-entity-boundaries", "name": "Related entity boundaries", "description": "Separate the parent substance, metabolites and macitentan-containing products.", "findings": [ { "id": "substance-product-metabolite-separation", "name": "Substance, product and metabolite separation", "description": "Represent ingredients and metabolic transformations as relationships between distinct entities.", "questions": [ { "text": "Does the incoming name identify macitentan itself, a formulated product or a related metabolite?", "kind": "boundary", "id": "substance-product-metabolite-separation-q01" }, { "text": "Which evidence establishes the relationship without transferring the other entity's properties to macitentan?", "kind": "provenance", "id": "substance-product-metabolite-separation-q02" } ] } ] } ] }, { "id": "macitentan-material-behavior", "name": "Macitentan material behavior", "description": "Describe the physical form and conditions that govern usable macitentan material.", "rationale": "Macitentan is described as a crystalline powder insoluble in water, making form and dissolution conditions consequential. [FDA description](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204410s017lbl.pdf)", "layers": [ { "id": "solid-form-and-particles", "name": "Solid form and particles", "description": "Establish the observed solid state and particle characteristics of each lot.", "findings": [ { "id": "characterized-solid-material", "name": "Characterized solid material", "description": "Tie solid-form assignments to diffraction or thermal evidence and distinguish form changes from particle-size effects.", "questions": [ { "text": "What measurements establish this lot's solid form, water or solvent content and particle-size distribution?", "kind": "measurement", "id": "characterized-solid-material-q01" }, { "text": "Which observed differences would require requalification before the intended analytical or pharmaceutical use?", "kind": "action", "id": "characterized-solid-material-q02" } ] } ] }, { "id": "dissolution-and-stability", "name": "Dissolution and stability", "description": "Record conditions under which macitentan dissolves and retains its measured composition.", "findings": [ { "id": "condition-qualified-usability", "name": "Condition-qualified usability", "description": "Keep bulk-solid stability, solution stability and finished-product storage evidence separate.", "questions": [ { "text": "What solubility and precipitation behavior are measured at the intended solvent composition, pH, temperature and concentration?", "kind": "measurement", "id": "condition-qualified-usability-q01" }, { "text": "What evidence supports storage conditions and a usable lifetime for this bulk material or prepared solution?", "kind": "provenance", "id": "condition-qualified-usability-q02" } ] } ] } ] }, { "id": "macitentan-lot-quality", "name": "Macitentan lot quality", "description": "Determine whether a particular lot meets requirements for its declared use.", "rationale": "Correct molecular identity does not establish adequate purity, traceability or pharmaceutical suitability.", "layers": [ { "id": "assay-and-related-substances", "name": "Assay and related substances", "description": "Quantify parent content and resolve relevant accompanying compounds.", "findings": [ { "id": "selective-quality-measurements", "name": "Selective quality measurements", "description": "Require methods capable of distinguishing macitentan from relevant related substances and degradation products.", "questions": [ { "text": "How is macitentan content quantified, and are water, residual solvents and reporting basis accounted for?", "kind": "measurement", "id": "selective-quality-measurements-q01" }, { "text": "Which impurities and degradation products must the method resolve, and what evidence supports their limits?", "kind": "provenance", "id": "selective-quality-measurements-q02" } ] } ] }, { "id": "traceability-and-release", "name": "Traceability and release", "description": "Connect sample history and quality evidence to a permitted use.", "findings": [ { "id": "use-specific-lot-disposition", "name": "Use-specific lot disposition", "description": "Treat research reagent, reference standard and pharmaceutical ingredient suitability as distinct determinations.", "questions": [ { "text": "Which manufacturer, lot history, certificate and reference-standard qualification support this material's declared grade?", "kind": "provenance", "id": "use-specific-lot-disposition-q01" }, { "text": "Does the lot meet the applicable use-specific specification, or must it remain quarantined or undergo retesting?", "kind": "action", "id": "use-specific-lot-disposition-q02" } ] } ] } ] }, { "id": "macitentan-biological-action", "name": "Macitentan biological action", "description": "Relate the parent substance to receptor effects and biologically relevant exposure.", "rationale": "Macitentan antagonizes ETA and ETB receptors and has a pharmacologically active metabolite. [FDA pharmacology](https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/204410s017lbl.pdf)", "layers": [ { "id": "endothelin-receptor-pharmacology", "name": "Endothelin receptor pharmacology", "description": "Capture receptor-specific evidence with its experimental context.", "findings": [ { "id": "contextualized-receptor-antagonism", "name": "Contextualized receptor antagonism", "description": "Distinguish binding measurements, functional antagonism and downstream biological responses.", "questions": [ { "text": "What ETA and ETB activity was measured, in which species and assay system, and using which endpoint?", "kind": "measurement", "id": "contextualized-receptor-antagonism-q01" }, { "text": "What evidence permits comparison with another endothelin antagonist under matched experimental conditions?", "kind": "boundary", "id": "contextualized-receptor-antagonism-q02" } ] } ] }, { "id": "parent-metabolite-exposure", "name": "Parent and metabolite exposure", "description": "Track metabolism and exposure without collapsing distinct analytes.", "findings": [ { "id": "separate-exposure-and-interaction-evidence", "name": "Separate exposure and interaction evidence", "description": "Associate concentrations and interaction findings with the measured analyte, regimen and study population.", "questions": [ { "text": "Which measurements separately quantify macitentan and its active metabolite, including sampling times and total or unbound concentration?", "kind": "measurement", "id": "separate-exposure-and-interaction-evidence-q01" }, { "text": "How do CYP3A4 or combined CYP3A4/CYP2C9 interactions change exposure, and which current label governs the resulting constraint?", "kind": "action", "id": "separate-exposure-and-interaction-evidence-q02" } ] } ] } ] }, { "id": "macitentan-hazards-and-use-constraints", "name": "Macitentan hazards and use constraints", "description": "Connect macitentan-specific risks to handling decisions and applicable medicinal-product records.", "rationale": "Labeling identifies embryo-fetal toxicity, hepatic concerns, fluid retention and hemoglobin decreases; bulk-material controls require their own evidence. [DailyMed label](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=226049ba-9c76-0798-6725-ee027a041820)", "layers": [ { "id": "bulk-material-exposure", "name": "Bulk material exposure", "description": "Assess exposure during weighing, transfer, solution preparation and disposal.", "findings": [ { "id": "evidence-based-handling-controls", "name": "Evidence-based handling controls", "description": "Establish controls from an applicable SDS and exposure assessment rather than translating a therapeutic dose into a workplace limit.", "questions": [ { "text": "Which dated SDS and jurisdiction-specific classification apply to this macitentan material and concentration?", "kind": "provenance", "id": "evidence-based-handling-controls-q01" }, { "text": "What containment, protective measures and waste route follow from the operation's dust, splash and reproductive-exposure assessment?", "kind": "action", "id": "evidence-based-handling-controls-q02" } ] } ] }, { "id": "dated-pharmaceutical-authority", "name": "Dated pharmaceutical authority", "description": "Link the substance to current product-level approvals and use restrictions.", "findings": [ { "id": "jurisdiction-specific-use-boundaries", "name": "Jurisdiction-specific use boundaries", "description": "Version approval scope and safety requirements by jurisdiction and product without making them intrinsic material properties.", "questions": [ { "text": "Which current approval and label establish the indication, eligible population and restrictions for the linked macitentan product?", "kind": "provenance", "id": "jurisdiction-specific-use-boundaries-q01" }, { "text": "Which pregnancy-related, hepatic, hematologic and interaction requirements must the linked clinical workflow check before use?", "kind": "action", "id": "jurisdiction-specific-use-boundaries-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This description is recalled knowledge; no sources were consulted.", "Verify current jurisdiction-specific labeling, indications and pregnancy-prevention requirements.", "Physical constants, solid forms, purity specifications and substance-level GHS classifications require verification before inclusion." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of macitentan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (WHO INN)", "value_or_pattern": "macitentan", "note": "Names the active substance rather than a finished medicinal product." }, { "scheme": "CAS Registry Number", "value_or_pattern": "441798-33-0", "note": "Chemical substance identifier." }, { "scheme": "WHO Anatomical Therapeutic Chemical classification", "value_or_pattern": "C02KX04", "note": "Therapeutic classification code for macitentan." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of macitentan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-standards-and-regulation", "name": "Standards and regulation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "US Food and Drug Administration prescribing information governs approved macitentan products and includes embryo-fetal toxicity warnings.", "European Union product information authorized through the European Medicines Agency specifies indications, contraindications and risk-management requirements." ], "questions": [ { "id": "evidence-standards-and-regulation-q01", "text": "Which of these standards and regulation hold for the sense of macitentan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Treatment of pulmonary arterial hypertension, classified as WHO Group 1 pulmonary hypertension.", "Use alongside medicines targeting other pulmonary arterial hypertension pathways, including phosphodiesterase type 5 inhibitors." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of macitentan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-measurements", "name": "Typical measurements", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "quantity": "Molar mass", "typical_range": "588.27", "unit": "g/mol" } ], "questions": [ { "id": "evidence-measurements-q01", "text": "Which of these typical measurements hold for the sense of macitentan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Embryo-fetal toxicity; use during pregnancy is contraindicated.", "Reduced hemoglobin concentration and anemia.", "Fluid retention and peripheral edema.", "Potential liver injury and elevations in liver aminotransferases.", "Drug interactions involving CYP3A4 inhibitors or inducers can substantially alter exposure." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of macitentan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-regional-variation", "name": "Regional variation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Approved indications, available formulations and pregnancy-prevention requirements depend on jurisdiction and product authorization." ], "questions": [ { "id": "evidence-regional-variation-q01", "text": "Which of these regional variation hold for the sense of macitentan this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "bosentan", "difference": "Another dual endothelin receptor antagonist, but a distinct chemical substance with different pharmacokinetic and interaction characteristics." }, { "name": "ambrisentan", "difference": "Preferentially antagonizes ETA receptors, whereas macitentan antagonizes both ETA and ETB receptors." }, { "name": "Opsumit", "difference": "A brand of medicinal product containing macitentan; the product includes a dosage form and excipients." }, { "name": "aprocitentan", "difference": "A distinct endothelin receptor antagonist that is also an active metabolite of macitentan." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of macitentan this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative EC and jurisdiction-specific substance identifiers should accompany the verified CAS and PubChem identities?", "Which macitentan solid forms are experimentally established, and what evidence determines whether their differences affect intended use?", "What reliable measurements establish pH-dependent solubility, thermal transitions and decomposition behavior for characterized material?", "Which current compendial or approved specifications govern macitentan assay, related substances, residual solvents and retest periods for each intended grade?", "What authoritative bulk-material GHS classifications, occupational exposure limits or exposure bands, and environmental disposal requirements apply in the target jurisdiction?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 18, "questions": 28 } }